BCLI vs. CYTH, TARA, ESLA, INAB, CRTX, ACHL, OKYO, SABS, INKT, and NKGN
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Cyclo Therapeutics (CYTH), Protara Therapeutics (TARA), Estrella Immunopharma (ESLA), IN8bio (INAB), Cortexyme (CRTX), Achilles Therapeutics (ACHL), OKYO Pharma (OKYO), SAB Biotherapeutics (SABS), MiNK Therapeutics (INKT), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.
Cyclo Therapeutics (NASDAQ:CYTH) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, community ranking, dividends, media sentiment, institutional ownership and valuation.
Cyclo Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.
Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Cyclo Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Brainstorm Cell Therapeutics received 284 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Cyclo Therapeutics an outperform vote while only 64.02% of users gave Brainstorm Cell Therapeutics an outperform vote.
68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cyclo Therapeutics currently has a consensus price target of $3.30, suggesting a potential upside of 153.85%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cyclo Therapeutics is more favorable than Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Brainstorm Cell Therapeutics' net margin of -1,864.03%. Cyclo Therapeutics' return on equity of 0.00% beat Brainstorm Cell Therapeutics' return on equity.
In the previous week, Cyclo Therapeutics had 4 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for Cyclo Therapeutics and 2 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.17 beat Cyclo Therapeutics' score of -0.50 indicating that Cyclo Therapeutics is being referred to more favorably in the media.
Summary
Cyclo Therapeutics beats Brainstorm Cell Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
